Adverse reactions associated with nivolumab and small molecule antiangiogenic drugs: A pharmacovigilance analysis
British Journal of Clinical Pharmacology · 2025
DOI: 10.1111/bcp.16242 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Haiyang Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Nivolumab, Angiogenesis Inhibitors, Pharmacovigilance, Adverse Drug Reaction Reporting Systems. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: Capital Health Research and Development of Special Fund, National Natural Science Foundation of China, Beijing Medical Award Foundation.
Abstract (Originalsprache)
Aims
Immune checkpoint inhibitors, such as nivolumab, combined with small molecule antiangiogenic receptor tyrosine kinase inhibitors (TKIs), present a promising strategy for future immunotherapy. However, combination therapy can lead to specific adverse drug reactions (ADRs) in various clinical settings. Current research on the ADRs associated with combination therapy is limited. Our study aims to assess the safety of combination therapy.
Methods
We extracted ADR reports on combination therapy from the Food and Drug Administration (FDA) Adverse Event Reporting System database, covering the period from the first quarter of 2012 to the third quarter of 2023, and conducted a large‐scale retrospective study. We evaluated ADR risk signals using the reporting odds ratio (ROR) and calculated the Ro/e ratio to compare the differences in the risk of fatal ADRs among various tumour types.
Results
We comprehensively reported the occurrence of ADRs in pan‐cancer patients undergoing combination therapy. The combination therapy significantly increased the risk of sensitive skin (ROR: 231.43, 95% CI: 55.01–973.72, P < .05), metastatic renal cell carcinoma (ROR: 220.71, 95% CI: 28.99–1695.41, P < .05) and renal cell carcinoma (ROR: 188.22, 95% CI: 44.24–800.85, P < .05). We also compared the differences in ADRs resulting from different small molecule drug combinations, as well as the differences in ADRs among patients with different types of tumours under combination therapy. Furthermore, we analysed the characteristics of patients prone to experiencing fatal ADRs.
Conclusion
These results can help enhance understanding of the ADRs commonly associated with combination therapy and assist oncologists in formulating screening protocols.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otorhinolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
- Changping Laboratory, Beijing, China.
- Department of Hepatobiliary and Pancreatic Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
- Zhanggongshan Communist Labour University, Shangrao, China.
ORCID-Profile: Jugao Fang
Förderung
- Capital Health Research and Development of Special Fund
- National Natural Science Foundation of China
- Beijing Medical Award Foundation
- Beijing Municipal Administration of Hospitals Incubating Program
Zitieren
APA
Li, H., Ruan, Z., Jia, Y., Zhang, Y., Wang, L., Yang, Y., Wang, R., & Fang, J. (2025). Adverse reactions associated with nivolumab and small molecule antiangiogenic drugs: A pharmacovigilance analysis. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16242
Vancouver
Li H, Ruan Z, Jia Y, Zhang Y, Wang L, Yang Y, et al. Adverse reactions associated with nivolumab and small molecule antiangiogenic drugs: A pharmacovigilance analysis. British Journal of Clinical Pharmacology. 2025. doi:10.1111/bcp.16242
BibTeX
@article{Li2025,
author = {Li, Haiyang and Ruan, Zhaohui and Jia, Yanan and Zhang, Yuan and Wang, Lingwa and Yang, Yifan and Wang, Ru and Fang, Jugao},
title = {Adverse reactions associated with nivolumab and small molecule antiangiogenic drugs: A pharmacovigilance analysis},
journal = {British Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1111/bcp.16242}
}
EUVIMED